Form 4: Senti Biosciences Director Fran Schulz Acquires 12,500 Stock Options

Director Fran Schulz of Senti Biosciences acquired 12,500 stock options on December 9, 2024, which vest over three years.

Summary

• Fran Schulz, a director at Senti Biosciences, acquired 12,500 stock options on December 9, 2024.
• The exercise price of these options is $6.52 per share.
• The options vest in 36 equal monthly installments over three years, starting from December 9, 2024.
• The options expire on December 8, 2034.
• The acquisition was reported on a Form 4 filing with the SEC.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of a stock option grant, which is neither particularly positive nor negative. It is a standard practice and does not indicate any significant change in the company's outlook.

Positives

• The acquisition of stock options by a director can be seen as a positive sign of confidence in the company's future.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders acquire or dispose of company securities. It is a routine disclosure and does not indicate any specific industry trend.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in publicly traded companies, particularly in the biotech sector, to align their interests with those of shareholders.
• The vesting schedule of three years is also a typical arrangement for such grants.
• The exercise price of $6.52 is specific to Senti Biosciences and would need to be compared to other similar companies to assess its relative value.

Stakeholder Impact

• The stock option grant may have a minor positive impact on shareholder sentiment, as it aligns the director's interests with those of the shareholders.

Key Dates

Keywords

stock options, insider trading, Senti Biosciences, director, equity, Form 4, vesting